Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA® registry

Abstract The AVIDA registry evaluated azacitidine usage and effectiveness in unselected patients with myelodysplastic syndromes (MDS) in community practice. Treating physicians made all treatment decisions. Hematologic improvement (HI) and transfusion independence (TI) assessments used International...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2015-04, Vol.56 (4), p.887-895
Main Authors: Grinblatt, David L., Sekeres, Mikkael A., Komrokji, Rami S., Swern, Arlene S., Sullivan, Kristen A., Narang, Mohit
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic - adverse effects
Antimetabolites, Antineoplastic - therapeutic use
AVIDA
azacitidine
Azacitidine - adverse effects
Azacitidine - therapeutic use
Female
Follow-Up Studies
Humans
lower-risk MDS
Male
Middle Aged
myelodysplastic syndromes
Myelodysplastic Syndromes - drug therapy
Outcome Assessment (Health Care) - statistics & numerical data
Prospective Studies
Quality of Life
Registries - statistics & numerical data
Risk Factors
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The AVIDA registry evaluated azacitidine usage and effectiveness in unselected patients with myelodysplastic syndromes (MDS) in community practice. Treating physicians made all treatment decisions. Hematologic improvement (HI) and transfusion independence (TI) assessments used International Working Group (IWG) 2000 criteria. Enrolled were 421 patients with MDS (n = 228 International Prognostic Scoring System [IPSS] lower-risk, n = 106 higher-risk, 86 patients unclassified) from 105 US sites. Median follow-up was 7.6 months (range: 0.1-27.6). HI and red blood cell TI rates were similar regardless of administration route or dosing schedule. Safety and tolerability were consistent with previous reports. The AVIDA registry data support azacitidine effectiveness and safety in patients with lower- or higher-risk MDS treated in community practice.
ISSN:1042-8194
1029-2403
DOI:10.3109/10428194.2014.935366